CT-P53 vs Ocrelizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: CD20 · full Multiple Sclerosis pipeline

CT-P53

Developed by Celltrion

Phase 3 in Multiple Sclerosismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT05906992 (registry estimate)

No aligned efficacy figure on record for this race.

Ocrelizumab

Marketed by Roche

Approved in Multiple Sclerosismonoclonal antibody
Partial signal

NCT00676715 · Phase 2 · completed

Randomized, double-blind phase 2 in relapsing-remitting multiple sclerosis (220 participants). Both ocrelizumab doses reduced gadolinium-enhancing brain lesions decisively versus placebo (p<0.0001); the endpoint is an MRI biomarker rather than a clinical relapse or disability outcome, which is why the grade is moderate despite the clear result.

Next expected readout: December 2026 · NCT04466150 (registry estimate)

Reported efficacy

Protocol-defined Annualized Relapse Rate (ARR) (Up to after the last participant randomized completed 24 weeks since first study treatment administration (up to approximately 160 weeks)): Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk. (met)

Result source: NCT05123703

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCT-P53Ocrelizumab
Annualised relapse rate—Trial running · NCT059069920.2 vs 0.3vs Interferon Beta-1awk 96 · n 410NCT01247324
3 other results
  • 0.2 vs 0.3 wk 96 · n 417 · Phase 3 · primary NCT01412333
  • 0.1 vs 0.6 600 mg / 600 mg · wk 24 · n 55 · Phase 2 · secondary NCT00676715
  • 0.2 vs 0.6 1000 mg / 600 mg · wk 24 · n 55 · Phase 2 · secondary NCT00676715
Free of 3-month confirmed disability progression (%)—Trial running · NCT05906992—Trial running · NCT05834855
New or enlarging T2 lesions—Trial running · NCT05906992430 vs 1916vs Interferon Beta-1awk 96 · n 410NCT01247324
1 other result
  • 380 vs 2103 wk 96 · n 417 · Phase 3 · secondary NCT01412333

Annualised relapse rate

CT-P53
—Trial running · NCT05906992
Ocrelizumab
0.2 vs 0.3vs Interferon Beta-1awk 96 · n 410NCT01247324
3 other results
  • 0.2 vs 0.3 wk 96 · n 417 · Phase 3 · primary NCT01412333
  • 0.1 vs 0.6 600 mg / 600 mg · wk 24 · n 55 · Phase 2 · secondary NCT00676715
  • 0.2 vs 0.6 1000 mg / 600 mg · wk 24 · n 55 · Phase 2 · secondary NCT00676715

Free of 3-month confirmed disability progression (%)

CT-P53
—Trial running · NCT05906992
Ocrelizumab
—Trial running · NCT05834855

New or enlarging T2 lesions

CT-P53
—Trial running · NCT05906992
Ocrelizumab
430 vs 1916vs Interferon Beta-1awk 96 · n 410NCT01247324
1 other result
  • 380 vs 2103 wk 96 · n 417 · Phase 3 · secondary NCT01412333
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CT-P53: no structured comparison results are available for Multiple Sclerosis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. CT-P53: 0 of 4 rows · Ocrelizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOcrelizumab
Dropout rate
16.4%600 mg / 600 mga
NCT00676715 · Phase 2
show 25 more results
—600 mg
NCT00676715 · Phase 2
—600 mg / 600 mg
NCT00676715 · Phase 2
21.8%1000 mg / 600 mg
NCT00676715 · Phase 2
—1000 mg / 600 mg
NCT00676715 · Phase 2
55.3%600 mg
NCT01194570 · Phase 3
—DB OCRELIZUMAB
NCT01194570 · Phase 3
—OLE OCRELIZUMAB
NCT01194570 · Phase 3
—OLE PLACEBO
NCT01194570 · Phase 3
41.7%Ocrelizumab
NCT01247324 · Phase 3
—Ocrelizumab + Placebo (Double Blin
NCT01247324 · Phase 3
—Ocrelizumab + Placebo (Open Label
NCT01247324 · Phase 3
7.7%
NCT04998851 · Phase 4 · registry result, not featured evidence
0%
NCT04261790 · Phase 4 · registry result, not featured evidence
10%
NCT03853746 · Phase 4 · registry result, not featured evidence
96.8%PPMS Cohort: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
100%RMS Cohort Arm 1: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
100%RMS Cohort Arm 2: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
100%RMS Cohort Arm 3: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
100%RMS Cohort Arm 4: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
—Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
—Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
5.7%
NCT02861014 · Phase 3 · registry result, not featured evidence
36%Ocrelizumab
NCT02637856 · Phase 3 · registry result, not featured evidence
—Ocrelizumab (Substudy)
NCT02637856 · Phase 3 · registry result, not featured evidence
7%
NCT02980042 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
5.5%600 mg / 600 mga
NCT00676715 · Phase 2
show 25 more results
—600 mg
NCT00676715 · Phase 2
—600 mg / 600 mg
NCT00676715 · Phase 2
3.6%1000 mg / 600 mg
NCT00676715 · Phase 2
—1000 mg / 600 mg
NCT00676715 · Phase 2
8.2%600 mg
NCT01194570 · Phase 3
—DB OCRELIZUMAB
NCT01194570 · Phase 3
—OLE OCRELIZUMAB
NCT01194570 · Phase 3
—OLE PLACEBO
NCT01194570 · Phase 3
8.5%Ocrelizumab
NCT01247324 · Phase 3
—Ocrelizumab + Placebo (Double Blin
NCT01247324 · Phase 3
—Ocrelizumab + Placebo (Open Label
NCT01247324 · Phase 3
—
NCT04998851 · Phase 4 · registry result, not featured evidence
—
NCT04261790 · Phase 4 · registry result, not featured evidence
—
NCT03853746 · Phase 4 · registry result, not featured evidence
0%PPMS Cohort: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
4.3%RMS Cohort Arm 1: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
6.5%RMS Cohort Arm 2: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
7.1%RMS Cohort Arm 3: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
0%RMS Cohort Arm 4: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
—Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
—Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
1%
NCT02861014 · Phase 3 · registry result, not featured evidence
1.5%Ocrelizumab
NCT02637856 · Phase 3 · registry result, not featured evidence
—Ocrelizumab (Substudy)
NCT02637856 · Phase 3 · registry result, not featured evidence
—
NCT02980042 · Phase 3 · registry result, not featured evidence
Serious AEs
—600 mg / 600 mga
NCT00676715 · Phase 2
show 25 more results
27.2%600 mg
NCT00676715 · Phase 2
30.9%600 mg / 600 mg
NCT00676715 · Phase 2
—1000 mg / 600 mg
NCT00676715 · Phase 2
29.1%1000 mg / 600 mg
NCT00676715 · Phase 2
—600 mg
NCT01194570 · Phase 3
21.4%DB OCRELIZUMAB
NCT01194570 · Phase 3
45.3%OLE OCRELIZUMAB
NCT01194570 · Phase 3
37.3%OLE PLACEBO
NCT01194570 · Phase 3
—Ocrelizumab
NCT01247324 · Phase 3
6.9%Ocrelizumab + Placebo (Double Blin
NCT01247324 · Phase 3
33%Ocrelizumab + Placebo (Open Label
NCT01247324 · Phase 3
0%
NCT04998851 · Phase 4 · registry result, not featured evidence
0%
NCT04261790 · Phase 4 · registry result, not featured evidence
0%
NCT03853746 · Phase 4 · registry result, not featured evidence
29%PPMS Cohort: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
21.7%RMS Cohort Arm 1: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
16.1%RMS Cohort Arm 2: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
3.6%RMS Cohort Arm 3: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
27.8%RMS Cohort Arm 4: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
7%Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
34.6%Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
7.2%
NCT02861014 · Phase 3 · registry result, not featured evidence
7.7%Ocrelizumab
NCT02637856 · Phase 3 · registry result, not featured evidence
1.6%Ocrelizumab (Substudy)
NCT02637856 · Phase 3 · registry result, not featured evidence
8%
NCT02980042 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
600 mga
multiple sclerosis relapse 27.2% (placebo 48.1%)
covid-19 25.2% (placebo 22.2%)
infusion related reaction 22.3% (placebo 53.7%)
NCT00676715 · Phase 2
show 21 more results
600 mg / 600 mg
infusion related reaction 45.5% (placebo 53.7%)
multiple sclerosis relapse 34.5% (placebo 48.1%)
nasopharyngitis 27.3% (placebo 18.5%)
NCT00676715 · Phase 2
1000 mg / 600 mg
infusion related reaction 52.7% (placebo 53.7%)
multiple sclerosis relapse 38.2% (placebo 48.1%)
urinary tract infection 27.3% (placebo 25.9%)
NCT00676715 · Phase 2
infusion related reaction 39.9% (placebo 25.5%)
nasopharyngitis 24.1% (placebo 26.4%)
urinary tract infection 21.2% (placebo 23.8%)
NCT01194570 · Phase 3
urinary tract infection 34.4% (placebo 23.8%)
nasopharyngitis 27.1% (placebo 26.4%)
covid-19 20.6% (placebo 0%)
NCT01194570 · Phase 3
nasopharyngitis 30.4% (placebo 26.4%)
urinary tract infection 27.8% (placebo 23.8%)
infusion related reaction 25.3% (placebo 25.5%)
NCT01194570 · Phase 3
infusion related reaction 30.9%
upper respiratory tract infection 14.5%
urinary tract infection 12.7%
NCT01247324 · Phase 3
urinary tract infection 28.7%
covid-19 27.3%
upper respiratory tract infection 25.6%
NCT01247324 · Phase 3
covid-19 46.2%
infusion related reaction 23.1%
nasopharyngitis 23.1%
NCT04998851 · Phase 4 · registry result, not featured evidence
headache 30%
cough 20%
blood pressure fluctuation 10%
NCT04261790 · Phase 4 · registry result, not featured evidence
bronchitis 11.1%
congestion 11.1%
cough 11.1%
NCT03853746 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 41.9%
infusion related reaction 38.7%
arthralgia 35.5%
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
infusion related reaction 65.2%
upper respiratory tract infection 30.4%
covid-19 17.4%
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
sinusitis 32.3%
infusion related reaction 29%
headache 19.4%
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
infusion related reaction 57.1%
upper respiratory tract infection 35.7%
pain in extremity 17.9%
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 66.7%
infusion related reaction 61.1%
urinary tract infection 38.9%
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
infusion related reaction 37.9%
nasopharyngitis 19.2%
upper respiratory tract infection 15.6%
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 30.6%
covid-19 27.4%
nasopharyngitis 27.4%
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
infusion related reaction 43.2%
nasopharyngitis 30.9%
headache 22.6%
NCT02861014 · Phase 3 · registry result, not featured evidence
infusion related reaction 43.3%
urinary tract infection 14.5%
nasopharyngitis 10.5%
NCT02637856 · Phase 3 · registry result, not featured evidence
infusion related reaction 12.4%
fatigue 0%
headache 0%
NCT02637856 · Phase 3 · registry result, not featured evidence
upper respiratory infection 36%
headache 14%
nausea 14%
NCT02980042 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ocrelizumab

Gd-enhancing T1 Lesion 0.6 vs 5.6 placebo lesions @ 24wk600 mg / 600 mg
event count · lesions
NCT00676715 · Phase 2
show 3 more results
2.5 vs 8.7 placebo lesions @ 24wk600 mg / 600 mg
NCT00676715 · Phase 2
0.2 vs 5.6 placebo lesions @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
1.8 vs 8.7 placebo lesions @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
Annualized Relapse 0.127 vs 0.557 placebo per year @ 24wk600 mg / 600 mg
event rate · per year
NCT00676715 · Phase 2
show 3 more results
0.213 vs 0.557 placebo per year @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
0.156 vs 0.292 Interferon Beta-1a per year @ 96wk
NCT01247324 · Phase 3
0.155 vs 0.29 Interferon Beta-1a per year @ 96wk
NCT01412333 · Phase 3 · registry result, not featured evidence
Relapse Free 85.5% (n=55) vs 75.9% (n=54) placebo @ 24wk600 mg / 600 mg
responder rate · % of participants
NCT00676715 · Phase 2
show 1 more result
87.3% (n=55) vs 75.9% (n=54) placebo @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
T2 Lesion Volume -878.84 vs -112.31 placebo mm @ 24wk600 mg / 600 mg
absolute change · mm
NCT00676715 · Phase 2
show 1 more result
-600.89 vs -112.31 placebo mm @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
New Gadolinium-Enhancing T1 Lesion 0.8 vs 5.1 placebo lesions @ 24wk600 mg / 600 mg
event count · lesions
NCT00676715 · Phase 2
show 1 more result
0.8 vs 5.1 placebo lesions @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
Time to 3m Confirmed Disability Worsening NA vs NA placebo months600 mg
time to event · months
NCT01194570 · Phase 3
show 2 more results
NA vs NA Interferon Beta-1a months @ 108wk
NCT01247324 · Phase 3
NA vs NA Interferon Beta-1a months @ 104wk
NCT01412333 · Phase 3 · registry result, not featured evidence
Time to 6m Confirmed Disability Worsening NA vs NA placebo months600 mg
time to event · months
NCT01194570 · Phase 3
T25-FW 38.933% (n=473) vs 55.097% (n=239) placebo @ 120wk600 mg
percent change · % of baseline
NCT01194570 · Phase 3
MRI-T2 Lesion Volume -3.366% (n=464) vs 7.426% (n=234) placebo @ 120wk600 mg
percent change · % of baseline
NCT01194570 · Phase 3
Whole Brain Volume -0.902% (n=407) vs -1.093% (n=203) placebo @ 120wk600 mg
percent change · % of baseline
NCT01194570 · Phase 3
SF-36 PCS -0.731 vs -1.108 placebo score @ 120wk600 mg
absolute change · score
NCT01194570 · Phase 3
T1 Gadolinium Enhancing Lesion 21 vs 337 Interferon Beta-1a lesions @ 96wk
event count · lesions
NCT01247324 · Phase 3

+ 42 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CT-P53's landscape · Ocrelizumab's landscape